LIST OF FIGURES

Title of the figure	Page No.
Graphical abstract: Role of TLR signaling in HNSCC Progression	xi
Figure 1.1: Toll-like receptor signaling pathway.	14
Figure 2.1: Regions of head and neck	17
Figure 2.2: Statistics demonstrating incident cases and deaths of HNSCCs in India	18
Figure 2.3: Region wise burden of various cancers and their major cause in India	22
Figure 2.4: Mode of action of HPV E6 and E7 viral oncoproteins in malignant phenotype development	23
Figure 2.5: Chemical structure of cisplatin	30
Figure 2.6: Chemical structure of 5-FU	30
Figure 2.7: Chemical structure of docetaxel	30
Figure 2.8: EGFR signaling pathway.	32
Figure 2.9: Immune checkpoint pathways and mechanism of action of checkpoint inhibitors.	33
Figure 2.10: TLRs expression on different types of immune cells	34
Figure 2.11: Structure of a TLR	35
Figure 2.12: TLR signaling pathways	38
Figure 2.13: Domain structure of Human IRAK proteins with size, location and expression in cells.	39
Figure 2.14: Formation of Myddosome complex	40
Figure 2.15: Expression of IRAKs in tumors cells according to the data by protein	43
atlas	
Figure 2.16: Drug targets of the TLR signaling pathway and therapeutic strategies to inhibit the signaling	47
Figure 2.17: Structure of IRAK-4 kinase demonstrating the inhibitor binding site	50

Figure 2.18: Chemical structures of IRAK inhibitors in clinic	51
Figure 2.19: Chemical structure of IRAK-1 &-4 dual inhibitor used in this study	51
Figure 3.1: Probable role of TLR signaling in HNSCC progression	53
Figure 4.1: Schematic protocol for the development of triple chemo-resistant cell	58
line	
Figure 4.2: Schematic illustration for the development of triple chemo-resistant cell line	58
Figure 5.1: Expression of TLRs in HNSCC cell line HEp-2	66
Figure 5.2: Evaluation of IRAKs and their phosphorylated forms in HNSCC cell line HEp-2	68
-	
Figure 5.3: Effect of inhibition of the TLR signaling pathway on the viability of	70
HNSCC cell line HEp-2	, 0
Figure 5.4: Effect of inhibition of the TLR signaling pathway on survival related proteins of HNSCC cell line HEp-2	71
Figure 5.5: Effect of inhibition of the TLR signaling pathway on the proliferative	72
potential of HNSCC cell line HEp-2	, -
Figure 5.6: Effect of inhibition of the TLR signaling pathway on CSCs using	74
HNSCC cell line HEp-2	
Figure 5.7: Effect of inhibition of the TLR signaling pathway on BST-2 expression and association of BST-2 with CSCs in HNSCC cell line HEp-2	75
Figure 5.8: Effect of inhibition of the TLR signaling pathway on the EMT of HNSCC	
cell line HEp-2	76
Figure 5.9: Effect of inhibition of the TLR signaling pathway on the metastasis of	
HNSCC cell line HEp-2	77
Figure 5.10: Effect of chemo-drug treatment on the viability of HEp-2 cell line	78
Figure 5.11: Assessment of morphological features of chemo-resistant cell line	80
Figure 5.12: Validation of the acquired chemo-resistance of the developed triple-	81
chemo-resistant cell line	
Figure 5.13: Expression of TLRs in chemo-resistant HEp-2 cell line	82

Figure 5.14: Comparative analysis of mRNA expression of TLRs 1-10 on parent	02
and chemo-resistant HEp-2 cell line	83
Figure 5.15: IRAK-signaling in chemo-resistant HEp-2 cell line	84
Figure 5.16: Effect of IRAK-1 &-4 dual inhibitor treatment on the viability of	85
chemo-resistant HEp-2 cell line	
Figure 5.17: Effect of inhibition of the TLR signaling pathway on the expression of	87
survival related proteins of chemo-resistant HEp-2 cell line	07
Figure 5.18: Effect of inhibition of the TLR signaling pathway on the proliferative	88
potential of chemo-resistant HEp-2 cell line.	00
Figure 5.19: Effect of inhibition of the TLR signaling pathway on the CD44 and	90
Nanog expression of chemo-resistant HEp-2 cell line	90
Figure 5.20: Effect of inhibition of the TLR signaling pathway on the ALDH1	01
expression in chemo-resistant HEp-2 cell line	91
Figure 5.21: Effect of inhibition of the TLR signaling pathway on the BST-2	01
expression of chemo-resistant HEp-2 cell line	91
Figure 5.22: Effect of inhibition of the TLR signaling pathway on the EMT of	93
chemo-resistant HEp-2 cell line	75
Figure 5.23: Effect of inhibition of the TLR signaling pathway on metastasis of	94
chemo-resistant HEp-2 cell line	74
Figure 5.24: Effect of combination treatment of docetaxel and IRAK-1 &-4 dual	96
inhibitor on the viability of parent and chemo-resistant HEp-2 cell lines	90
Figure 5.25: Effect of combination treatment of cisplatin and IRAK-1 &-4 dual	97
inhibitor on the viability of parent and chemo-resistant HEp-2 cell lines	91
Figure 5.26: Effect of combination treatment of 5-FU and IRAK-1 &-4 dual inhibitor	00
on the viability of parent and chemo-resistant HEp-2 cell lines	98
Figure 5.27: Effect of combination treatment of individual chemo-drugs and IRAK-	
1 &-4 dual inhibitor on the mRNA fold expression of Bcl-2 and Bcl-xL of chemo-	100
resistant HEp-2 cell line	100
Figure 5.28: Representative histogram images demonstrating the effect of	
combination treatment of individual chemo-drugs and IRAK-1 &-4 dual inhibitor on	100
the Ki-67 expression of parent and chemo-resistant HEp-2 cell lines	102

Figure 5.29: Effect of combination treatment of individual chemo-drugs and IRAK-	
1 &-4 dual inhibitor on the Ki-67 expression of parent and chemo-resistant HEp-2	102
cell lines	103
Figure 5.30: Representative histogram images demonstrating the effect of	
combination treatment of individual chemo-drugs and IRAK-1 &-4 dual inhibitor on	105
the CD44 expression of parent and chemo-resistant HEp-2 cell lines	105
Figure 5.31: Effect of combination treatment of individual chemo-drugs and IRAK-	
1 &-4 dual inhibitor on the CD44 expression of parent and chemo-resistant HEp-2	100
cell lines	106
Figure 5.32: Representative histogram images demonstrating the effect of	
combination treatment of individual chemo-drugs and IRAK-1 &-4 dual inhibitor on	100
the Nanog expression of parent and chemo-resistant HEp-2 cell lines	108
Figure 5.33: Effect of combination treatment of individual chemo-drugs and IRAK-	
1 &-4 dual inhibitor on the Nanog expression of parent and chemo-resistant HEp-2	100
cell lines	109
Figure 5.34: Effect of combination treatment of individual chemo-drugs and IRAK-	110
1 &-4 dual inhibitor on the ALDH1 expression of chemo-resistant HEp-2 cell line	110
Figure 5.35: Effect of combination treatment of individual chemo-drugs and IRAK-	110
1 &-4 dual inhibitor on the E-cadherin expression of chemo-resistant HEp-2 cell line	112
Figure 5.36: Effect of combination treatment of individual chemo-drugs and IRAK-	110
1 &-4 dual inhibitor on the Vimentin expression of chemo-resistant HEp-2 cell line	113
Figure 5.37: Effect of combination treatment of individual chemo-drugs and IRAK-	
1 &-4 dual inhibitor on the mRNA fold expression of MMP-2 mRNA and IL-6 levels	
of chemo-resistant HEp-2 cell line	115
Figure 5.38: Representative histogram images showing the effect of combination	
treatment of individual chemo-drugs and IRAK-1 &-4 dual inhibitor on the BST-2	
expression of parent and chemo-resistant HEp-2 cell lines	117
Figure 5.39: Effect of combination treatment of individual chemo-drugs and IRAK-	
1 &-4 dual inhibitor on the BST-2 expression of parent and chemo-resistant HEp-2	
cell lines	118
Figure 6.1: TCGA data-based analysis of BST-2 expression in	
HNSCC	121